Clinical Trial Update: Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating a new oral formulation of cladribine (MyClad) versus placebo in generalized myasthenia gravis, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• Cladribine (cladribine)

Snippet

Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Conditions: Generalized Myasthenia Gravis | Phase 3 | Status: RECRUITING